CHARLOTTE, N.C. - Prenetics Global Limited (NASDAQ:PRE) announced Tuesday it has entered into warrant exchange agreements with holders representing approximately 83.4% of its outstanding Class A and ...
Placebo-adjusted mean weight loss of 11.3% (27.3 lbs) with 120 mg dose in the 36-week Phase 2b ACCESS study with a 10.4% adverse event-related treatment discontinuation Placebo-adjusted mean weight ...
SAN FRANCISCO, Dec. 08, 2025 (GLOBE NEWSWIRE) -- Structure Therapeutics Inc. (NASDAQ: GPCR), a clinical-stage global biopharmaceutical company developing novel oral small molecule therapeutics for ...
SAN FRANCISCO, Dec. 07, 2025 (GLOBE NEWSWIRE) -- Structure Therapeutics Inc. (NASDAQ: GPCR), a clinical-stage global biopharmaceutical company developing novel oral small molecule therapeutics for ...
Defense Secretary Pete Hegseth outlined plans Friday for a sweeping revamp of the military's acquisition systems, which he described as sluggish and mired in bureaucracy. (Julia Demaree Nikhinson/AP) ...
Albany International Initiates Review of Strategic Alternatives for Structures Assembly Business; Announces Loss Reserve Adjustment for CH-53K Program; Schedules Earnings Release Date Third-Quarter ...
Billy Gonzales now knows what his offensive staff structure will look like for the Gators' final five games of the season. GAINESVILLE, Fla.-- On Monday, Florida Gators interim head coach Billy ...
Placebo-adjusted mean weight loss of 11.3% (27.3 lbs) with 120 mg dose in the 36-week Phase 2b ACCESS study with a 10.4% adverse event-related treatment discontinuation Placebo-adjusted mean weight ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback